0001104659-19-021850.txt : 20190417
0001104659-19-021850.hdr.sgml : 20190417
20190417093550
ACCESSION NUMBER: 0001104659-19-021850
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190417
FILED AS OF DATE: 20190417
DATE AS OF CHANGE: 20190417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Danilkovitch Alla
CENTRAL INDEX KEY: 0001636236
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32966
FILM NUMBER: 19752332
MAIL ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
STREET 2: OSIRIS THERAPEUTICS, INC.
CITY: COLUMBIA
STATE: MD
ZIP: 21046
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OSIRIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001360886
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 710881115
STATE OF INCORPORATION: MD
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
CITY: COLUMBIA
STATE: MD
ZIP: 21046
BUSINESS PHONE: 443-545-1819
MAIL ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
CITY: COLUMBIA
STATE: MD
ZIP: 21046
4
1
a4.xml
4
X0306
4
2019-04-17
1
0001360886
OSIRIS THERAPEUTICS, INC.
OSIR
0001636236
Danilkovitch Alla
C/O OSIRIS THERAPEUTICS, INC.
7075 ALBERT EINSTEIN DRIVE
COLUMBIA
MD
21046
0
1
0
0
Chief Scientific Officer
Common Stock
2019-04-17
4
D
0
9375
19.00
D
0
D
Incentive Stock Option (right to buy)
7.74
2019-04-17
4
D
0
8000
0
D
2020-03-12
Common Stock
8000
0
D
Incentive Stock Option (right to buy)
6.46
2019-04-17
4
D
0
5000
0
D
2020-05-27
Common Stock
5000
0
D
Incentive Stock Option (right to buy)
7.13
2019-04-17
4
D
0
9000
0
D
2021-02-14
Common Stock
9000
0
D
Incentive Stock Option (right to buy)
5.08
2019-04-17
4
D
0
6000
0
D
2022-03-23
Common Stock
6000
0
D
Incentive Stock Option (right to buy)
7.73
2019-04-17
4
D
0
10000
0
D
2023-02-12
Common Stock
10000
0
D
Non-Qualified Stock Option (right to buy)
14.00
2019-04-17
4
D
0
1436
0
D
2024-05-06
Common Stock
1436
0
D
Incentive Stock Option (right to buy)
14.00
2019-04-17
4
D
0
18564
0
D
2024-05-06
Common Stock
18564
0
D
Incentive Stock Option (right to buy)
18.40
2019-04-17
4
D
0
7644
0
D
2025-03-06
Common Stock
7644
0
D
Non-Qualified Stock Option (right to buy)
18.40
2019-04-17
4
D
0
17356
0
D
2025-03-06
Common Stock
17356
0
D
Non-Qualified Stock Option (right to buy)
6.80
2019-04-17
4
D
0
24997
0
D
2027-07-19
Common Stock
24997
0
D
Incentive Stock Option (right to buy)
6.80
2019-04-17
4
D
0
25003
0
D
2027-07-19
Common Stock
25003
0
D
On March 12, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Smith & Nephew Consolidated, Inc., a Delaware corporation ("Parent"), Papyrus Acquisition Corp., a Maryland corporation and a direct subsidiary of Parent ("Purchaser") and Smith & Nephew plc, an English public limited company. Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired at a purchase price of $19.00 per share (the "Offer Price") in cash.
Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal to the excess, if any, of (A) the Offer Price over (B) the exercise price per share of such stock option, multiplied by the number of shares of Common Stock subject to such option.
/s/ Alla Danilkovitch
2019-04-17